MULTICENTER PROSPECTIVE CLINICAL TRIAL WITH LOW DOSE GEMTUZUMAB-OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN (GO-FLAI) AS INDUCTION THERAPY OF CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS YOUNGER THAN 65 YEARS

2.2.8. Candoni A.